04:05 AM EST, 03/04/2025 (MT Newswires) -- Evotec SE ( EVO ) said Tuesday that it has advanced its neuroscience collaboration with Bristol Myers Squibb ( BMY ) by securing a research payment of $20 million for further development of a pre-clinical program in neurodegeneration.

The two companies started their collaboration in December 2016 to develop transformative treatments that can slow or halt disease progression for a broad range of neurodegenerative diseases.